NOR-CHOLANIC ACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Abstract: Compounds (I) (either R1 = OH, C1-C4 alkoxy and R2 = H, C1-C4 alkyl, or R1 + R2 = a chemical bond; R3 = an aminodeoxy or aminodideoxy or aminotrideoxy sugar residue of the D and L series, the glycosidic linkage being alpha or beta : and either R4 = OH and R5 = H or R4 + R5 = a chemical bond) and their pharmaceutically acceptable salts are useful as antihypertensive agents. Their preparation and use as well as pharmaceutical compositions containing them are also described.

Description: Nor-cholanic acid derivatives, a process for their preparation, their use and pharmaceutical compositions containing them The invention provides aminoglycoside steroids having the αeneral formula I wherein either R represents a hydroxy group or an alkoxy group having f om 1 to 4 carbon atoms and R, represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms, or R, and R 2 taken together represent a chemi¬ cal bond; R_ represents an optionally alkyl-substituted aminodeoxy or aminodideoxy or aminotrideoxy sugar residue of the D or L series; and either R^ represents a hydroxy group and R 5 represents a hydrogen atom or R. and R 5 taken together represent a chemical bond. Such sugar resi¬ dues are, for example, 2-amino or 2-alkylamino-2-deoxy- hexopyranosyl, 3-amino or 3-alkylamino-3-deoxy-hexopyra- nosyl, 3-amino or 3-alkylamino-3,6-dideoxy-hexopyranosyl, 3-amino or 3-alkyl-amino-2,3,6-trideoxy-hexopyranosyl and 4-amino or 4-alkylamino-2,4,6-trideoxy-hexopyranosyl resi¬ dues of the D and L series. The optional alkyl substi- tuents of the sugar residue are preferably lower alkyl with c " C 4 atoms, e.g. methyl, ethyl, propyl and butyl. Advantageously the alkyl radicals may substitute the amino group of the sugar residue. The wavy lines in the formulae indicate that the hydrogen atom or the substituent may be above or under the plane of the ring system providing optically active isomer forms having different absolute configurations. These optically 5 active forms either in the form of the racemate or as pure optical antipodes are encompassed by this invention. The racemates can be separated " in accordance with methods known per se. Preferably the race ic mixture is reacted with an optically active separting agent to form diaster- 10 eomers. As separating agents e.g. optically active acids such as the D- and L-form of tartaric acid, diacetyl-tar- taric acid, dibenzoyl-tartaric acid, mandelic acid, malic acid, lactic acid or the various optically active campher- sulfonic acids like β-camphersulfonic acid may be mention- 15 ed. Of course it is also possible to obtain optically active compound ' s of formula I in utilizing starting materials being optically active. 20 The glycosidic linkage can be CL or β. An alkoxy group may be methoxy, ethoxy, propoxy or butoxy group, an alkyl group may be methyl, ethyl, propyl or butyl group. 25. Pharmaceutically acceptable salts of these aminoglycoside steroids are included in the invention. "Pharmaceutically acceptable salts" refers to those salts which retain the biological effectiveness and properties 30 of the free basis and which are not biologically or other¬ wise undesirable. Such- salts are formed with inorganic acids such as hydrochloric, hydrobro ic, sulfuric, nitric or phosphoric acid and organic acids such as acetic, propionic, glycolic, pyruvic, oxalic, malic, malonic, 35 succinic, maleic, fumaric, tartaric, citric, benzoic, cinna ic, mandelic, methanesulfonic, ethanesulfonic, p-toluene sulfonic or salicylic acid. The invention further provides a process for the prepara¬ tion of the aminoglycoside steroids of the general formula I as herein defined, which process comprises condensing a nor-cholane derivative having the general formula II wherein R. and R-. have the above meanings with a protected 1-halo derivative of an optionally alkyl sub¬ stituted aminodeoxy, aminodideoxy or aminotrideoxy sugar of the D or L series and removing the protecting groups from the resultant compound. The removal of the protecting group is advantageously obtained with a base. The condensation is desirably carried out in a suitable organic solvent, such as chloroform, methylene dichloride, benzene, toluene, acetonitrile or nitro ethane, in the presence of a catalyst. The catalyst may preferably by silver oxide or carbonate or trifluoromethanesulphonate, Fetizon's reagent, mercuric cyanide or bromide. In the process it may be desirable to use drierite or a molecular sieve as drying agents or the azeotropic distillation method during reaction, at a temperature of -5°C to 100°C. The reaction time may vary broadly and often be from one to eight hours. The base used to remove the protecting groups may be a hydroxide or methoxide of sodium or potassium or barium or may be triethylamine. and the reaction may be performed at room temperature over a period of some hours to several 5 days. This operation generally gives compounds of the general formula I wherein: R. is hydroxy or alkoxy group and R 2 is a hydrogen atom or alkyl group. These compounds may be TO converted by cyclization into the other compounds of the general formula I wherein R 2 and R 2 together represent a chemical bond, forming a lactone ring. The cyclization may be carried out in hydrochloric acid at room temperature • and pH 1-2 for from three to five hours. 15 The nor-cholane derivatives of the formula II and the aminodeoxy, a inodideoxy and aminotrideoxy sugars, possibly in alkylated form respectively, used a starting materials are well known compounds or they may be prepared 2.0 by procedures familiar to those skilled in the art. The aminoglycoside nor-cholanic acid derivatives according to the invention and their pharmaceutically acceptable salts are capable of inhibiting specific ouabain binding 25 . without inhibiting Na + , K -ATPase activity and thus they may form useful pharmaceutical compositions, particularly for the treatment of hypertension. Thus the inventive compounds may also be used for the making of medicaments effective against hypertension. 20 'In vitro' assays to test the ability of aminoglycoside steroids of formula I to displace specific ouabain binding + + to the (Na -K )-ATPase receptors without inhibiting the (Na -K )-ATPase enzymatic activity. 5 Radiochemical assay: A microso ial fraction enriched in (Na -K )-ATPase was prepared from dog kidney outer medulla, according to Jόrgensen (B3A 356: 36-52, 1974). The partially purified enzyme (0.5 μg of protein) was incubated in 3 M MgCl«. 3 mM EGTA, 80 mM Hepes buffer 1 32 (pH 7.4) and 2 mM y - P -ATP. final volume 110 μl, at 37 C for 15 minutes with increasing concentrations of ouabain (as reference compound) or aminoglycoside steroids. The reaction was stopped by the addition of 0.1 M of cold perchloric acid (10% final concentration) and 0.5 ml of charcoal suspension (20% w/v) . The suspension was 32 centrifuged and the content of P in the supernatant was measured by liquid scintillation counting. (ref. Mall F. et al.; Biochem. Pharm. 33: N.l, 47-53. 1984). The effects of various concentrations of aminoglycoside steroids and ouabain were expressed as a percentage of inhibition of the total (Na -K )-ATPase activity and IC, n values were calculated. The compounds of the formula I are inactive in this test. Displacement of ouabain (H ) binding from human red blood cells The procedure has been described elsewhere (Erdmann E. et al.; Arzneim. Forsh 34(11). no.10: 1314, 1984). Washed erythrocytes (about 1-1.8 x 10 9/ml) were incubated in 130 mM NaCl, 1 mM MgCl,, 10 mM glucose, 10 mM sucrose. 10 mM Tris/HCl buffer (pH 7.4) 2χlO~ 9 M 3 H ouabain and increasing concentration of the unlabelled aminoglycoside steroids, at 37°C for 5 hours. Bound ouabain was quantitated by a rapid filtration technique (Whatman GF/C glass filter membranes ; 'Whatman' is a Trade Mark) to separate free from membrane-bound ouabain. The radioactivity in the filters was determined by liquid scintillation counting Non specific binding was defined aass tthhee binding in the presence of 10 3 M unlabelled ouabain. 5 This dissociation constant (I value) was calculated from the concen¬ tration of unlabelled aminoglycoside steroids which inhibit H-ouabain bindung by 50% at equilibrium, by the method of Erdmann et al. (Schmiedeberg's Arch. Pharmacol. 283: 335, 1973). The compounds of the formula I are effective in this test with a P value range of from -9 -6 χ(j 10 to 10 . Inhibition of Na efflux mediated by the (Na -K )- -ATPase in human red blood cells The procedure has been described elsewhere (Garay et al .. Biochem. Pharmacol. 33:2013-2020, 1984). Washed red blood 15 " cells were suspended to a he atocrit of 20-25% in 74 mi-: MgCl 2 , 2 mM KC1, 84 mM sucrose, 10 mM MOPS/Tris buffer (pH 7.4 at 37°C) and 10 mM glucose. Red cell suspensions were added in the cold to tubes 2.0 containing Mg sucrose-K medium with increasing concentration of ouabain and fixed concentrations of aminoglyco's de steroids. The tubes were incubated at 37 C and aliquots of the suspensions were transferred to the cold and spun down at different times (0 - 10 - 20 - 30 2,5 minutes) . External Na concentrations were measured in the superna tents by atomic absorption. A kinetic analysis of the in¬ hibition of ouabain sensitive Na efflux as a function of different aminoglycoside concentrations was done and the IC--. for each compound was calculated. The compounds of the formula I are effective in a con- Jtt centration range from 10 ~ to 10 M. 'In vivo' assays to test the hypotensive activities of aminoglycoside steroids of formula I Indirect measurements of systolic blood pressure was carried out in groups of 4 spontaneously hypertensive rats £5 (SHR, Kyoto). 8 to 10 weeks of age, supplied by Charles Rives, Italy. The animals were maintained in an environment of 36°C for 10 to 15 minutes to allow pulse pressure to be recorded and then systolic blood pressure and heart rate were measured by the indirect tail cuff method using a W+W, BP recorder, model 8005. The compounds were given orally, suspended in 5% arabic gum, once a day for 4 consecutive days and measurements were carried out before beginning the treatment and 1 and 5 hours after dosing in both the first and fourth day of treatment. Control animals received the vehicle only (0.2 ml/100 g body weight) . Drug induced changes in systolic blood pressure were calculated as differences from the pretreatment values. The formulation of the compounds of the invention as pharmaceutical composition may include solid formulations such as capsules, tablets and powders, or liquid formula¬ tions such as elixirs, syrups and suspensions for oral administration. Alternatively, the inventive compounds (I) may be formulated as injections or suppositories. A carrier and diluent may be included in the pharmaceuti¬ cal composition which is selected from pulverulent solid carriers such as lactose, saccharose, dextrose, mannitol, sorbitol, cellulose, and glycine etc. The composition may further contain a lubricant, a binder or a disintegrator. Examples of suitable lubricants are silicon dioxide, talc, magnesium stearate and polyethylene glycol. Examples of suitable binders are starch, gelatin, tragacanth, methyl cellulose and polyvinyl pyrrolidone. Examples of suitable disintegrators are starch and agar etc. The following Examples illustrate preferred embodiments of the invention. EXAMPLE 1 3- Q 3-amino-3-deoxy-β-D-glucopyranosyl) oxyJ-1 4 , 21 -dihydroxy- - ( 3 β , 5 β , 14 β , 2QR) -24-nor-cholanic acid . 376 mg of 3,14,21-trihydroxy-(3β,5β,14β,20R)-24-nor-cholanic acid lactone were dissolved in 100 ml of anhydrous benzene, 3.4 g of Fetizon reagent were added, the mixture was brought to reflux and, with azeotropic distillation, a solution of 928 mg of 3-deoxy-2,4,6-tri-0-acetyl-3-trifluoroacetamido-α- -D-glucopyranosyl bromide in 100 ml of anhydrous benzene was added dropwise over 3 hours. The mixture was cooled to r.t., filtered, the organic solution washed with a saturated sodium hydrogen carbonate solution, with a saturated sodium chloride solution, dried over sodium sulfate and evaporated to dryness. .The crude residue was chromatographed on.silica gel with cy- clohexane-ethyl acetate 1:1 to afford 531 mg of 3- |_(3-deoxy- 2,4,6-tri-0-acetyl-3-trifluoroacetamido-α-D-glucopyranosyl)oxyj - -14,21-dihydroxy-(3β,5β,14β,20R)-24-nor-cholanic acid lactone. 53 ' 1 mg of the aforementioned protected glycoside were dissolved in 28 ml of 0.1 N potassium hydroxide in methanol-water 99:1. After 24 hours at r.t., the solution was evaporated to dryness, the residue dissolved in water and acidified at pH 5 by addition of acetic acid. The resulting precipitate was filtered, washed with water and dried to afford 300 mg of the title compound. EXAMPLE 2 3-C(3-amino-3-deoxy-β-D-glucopyranosyl)oxyJ-14,21-dihydroxy- -(3β,5β,14β,20R)-24-nor-cholanic acid lactone. 540 mg of 3- [(3-amino-3-deoxy-β-D-glucopyranosyl)oxyj-14,21- -dihydroxy-(3β,5β,14β,20R)-24-nor-cholanic acid were suspended in 150ml of distilled water and brought into solution acidify¬ ing at pH 1 with 1 N hydrochloric acid. After 1 hour at r.t. the solution was brought at pH 8 with a saturated sodium hydrogen carbonate solution, extracted with chloroform-methanol 8:2, the organic layer washed with a sa¬ turated sodium chloride solution, dried over sodium sulfate, evaporated to dryness and crystallized from absolute ethyl alcohol to afford 430 mg of the title compound, m.p. 278-282 C, EXAMPLE 3 3-[(3-amino-3-deoxy-β-D-qlucopyranosyl)oxy3-14,21-dihydroxy- -(3B,5g,14B,20S)-24-nor-cholanic acid. Operating as in Example 1 but employing 3,14,21-trihydroxy-(3β, 5β,1 β,20S)-24-nor-cholanic acid lactone, the title compound was obtained in 58% yield. EXAMPLE 4 3-C(3-amino-3-deoxy-β-D-glucopyranosyl)oxy^]-14,21-dihy- droxy-(3β,5β,14B-20S)-24-nor-cholanic acid lactone. Operating as in Example 2 but employing 3-{ " (3-amino-3- -deoxy-β-D-glucopyranosy1)oxyj -14,21-dihydroxy-(3β,5β, 14β,20S)-24-nor-cholanic acid, the title compound was obtained in 78% yield. EXAMPLE 5 3-L( 3-amino-3-deoxy-6-D-glucopyranosyl) oxyl -21 -hydroxy- 1 4 ( 3 β , 5 e , 20R) -Δ -24-nor-cholenic acid. Operating as in Example 1 but employing 3,21-dihydroxy- 1 144 ((33 ,,55ββ,,2200RR))--ΔΔ --2244--nnoorr--cchhoolleenniicc aacciid lactone, the title compound was obtained in 72% yield. EXAMPLE 6 3-C(3-amino-3-deoxy-β-D-σlucopyranosyl)oxyJ—21-hydroxy- 14 (3 ,5 ,20R)-Δ -24-nor-cholenic acid lactone. Operating as in Example 2 but employing 3-[_(3-amino-3- -deoxy-β-D-glucopyranosyl)oxyj-21-hydroxy-(3β,5β,20R) - 1 -Δ -24-nor-cholenic acid, the title compound was obtained in. 90% yield, m.p. 188-190°C. EXAMPLE 7 3-C(3-amino-3-deoxy-S-D-glucoρyranosyl)oxyl-21-hydroxy- 14 (3β,5β,20S)-Δ -24-nor-cholenic acid. Operating as in Example 1 but employing 3,21-dihydroxy- 1 144 --((33ββ,,55ββ,,2200SS))--ΔΔ --2244--nnoorr--cchhoolleenniicc aaccid lactone, the title compound was obtained in 69% yield. EXAMPLE 8 3-C(3-amino.-3-deoxy-S-D-glucopyranosyl)oxy]-21-hydroxy- 14 -(3B,5£,20S) -Δ -24-nor-cholenic acid lactone. Operating as in Example 2 but employing 3- (3-a_nino-3-deoxy- *ι 14 -6-D-glucopyranosyl)oxyj-21-hydroxy-(3β,5β,20S)-Δ -24-nor- -cholenic acid, the title compound was obtained in 79% yield, m.p.190-192°C. EXAMPLE 9 3- 2-amino-2-deoxy-β-D-glucopyranosyl)oxy]]-14 ,21-dihydroxy- -(3β,5B,14B,20R)-24-nor-cholanic acid. Operating as in Example 1 but employing 2-deoxy-3,4,6-tri-0- -acetyl-2-trifluoroaceta_nido-0C-D-glucopyranosyl bromide, the title compound was obtained in 52% yield. EXAMPLE 10 3-E(2-amino-2-deoxy-B-D-glucopyranosyl)oxy]-14,21-dihy- droxy-(3β,5β,14β,2QR)-24-nor-cholanic acid lactone. Operating as in Example 2 but employing 3- [(2-amino-2- -deoxy-β-D-glucopyranosyl)oxyj-14,21-dihydroxy-(3β,5β , 145,20R)-24-nor-cholanic acid, the title compound was obtained in 78% yield. EXAMPLE 11 3-C(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy3~ -14,21-dihydroxy-(3β,5β,14β,20R)-24-nor-cholanic acid. Operating as in Example 1 but employing 2,3,6-trideoxy- -3-trifluoroacetamido-4-0-trifluoroacetyl- -L-lyxo-hexo- pyranosyl chloride, the title compound was obtained in 63% yield. EXAMPLE 12 3-C(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxyj- -14,21-dihydroxy-(3β,5β,14β,20R)-24-nor-cholanic acid lactone. Operating as in Example 2 but employing 3-{_(3-amino-2,3,6- -trideoxy-α-L-lyxo-hexopyranosyl)oxyj-14,21-dihydroxy-(3B, 5B,14B,20R)-24-nor-cholanic acid, the title compound was obtained in 75% yield. EXAMPLE 1 3 3- (3-amino-2,3,6,trideoxy-α-L-lyxo-hexopyranosyl)oxyj- -14,21-dihydroxy-(3S,5B,14β,20S)-24-nor-cholanic acid. Operating as in Example 3 but employing 2,3,6-trideoxy- -3-trifluoroacetamido-4-0-trifluoroacetyl-α-lyxo-hexopy_ ranosyl chloride, the title compound was obtained in 60% yield. EXAMPLE 14 3-C(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]- -1 , 2 -dihydroxy-(3B,5β,14β,20S) -24-nor-cholanic acid lactone. Operating as in Example 2 but employing 3- (3-amino-2,3,6- -trideoxy-α-L-lyxo-hexopyranosyl)oxyJ-14,21-dihydroxy-(3β, 5β, 14β,20S)-24-nor-cholanic acid, the title compound was obtained in 74% yield. EXAMPLE 15 3-Q3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxyj-21- 14 -hydroxy-(3B,58,20R) -Δ -24-nor-cholenic acid. Operating as in Example 5 but employing 2,3,6-trideoxy-3- -trifluoroacetamido-4-O-trifluoroacetyl-α-L-lyxo-hexopy- ranosyl chloride, the title ^ compound was obtained in 70% yield. EXAMPLE 16 3-C(3-amiπo-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxyJ-21- 14 -hydroxy-(38,5B,2QR)-Δ -24-nor-cholenic acid lactone. Operating as in Example 2 but employing 3- (3-amino-2,3,6- •* ' -trideoxy-α-L-lyxo-hexopyranosyl)oxyJ-21-hydroxy-(3B,5B, 14 20R)-Δ -24-nor-cholenic acid, the title compound was obtained in 80% yield, m.p. 182-186°C. EXAMPLE 17 10 3-[_(3-amino-2,3,6-trideoxy-α-L-lyxo-hexoρyranosyl)oxyJ-21- 14 -hydroxy-(3B,5β,20S) -Δ -24-nor-cholenic acid. Operating as in Example-7 but employing 2,3,6-trideoxy-3-tri- fluoroacetamido-4-O-trifluoroacetyl-α-L-lyxo-hexopyranosyl chloride, a mixture of α and β-glycosides was obtained in 70% yield. By crystallization, ' the title compound was obtaiend in 40% yield, m.p.161-163°C. EXAMPLE 18 3- (3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy -21- 14 2° -hydroxy-(3B,5β,20S)-Δ -24-nor-cholenic acid lactone. Operating as in Example 2 but employing 3- [_(3-amino-2,3,6- trideoxy-α-L-lyxo-hexopyranosyl)oxyj-21-hydroxy-(3B,5B ,20S)- 14 -Δ -24-nor-cholenic acid, the title compound was obtained in 75% yield, m.p. 220-224°C. EXAMPLE 19 3-C(3-amino-2,3,6-trideoxy-β-L-lyxo-hexopyranosyl)oxy_3-21- 14 -hydroxy-(3β,5B,20S)-Δ -nor-cholenic acid. The residue of the mother liquors obtained in Example 17 was crystallized giving the title compound in 25% yield. EXAMPLE 20 3- Q(3-amino-2, 3,6-trideoxy-β-L-lyxo-hexopyranosyl)oxyJ-21- 14 -hydroxy- (3β, 5£,20S) -Δ -nor-cholenic acid lactone. Operating as in Example 2 but employing 3- [_(3-amino-2,3 ,6- -trideoxy-β-L-lyxo-hexopyranosyl)oxyj-21-hydroxy-(38,56,20S) 1 144 --ΔΔ --nnoorr--cc]holenic acid, the title compound was obtained in 76% yield. EXAMPLE 21 3-C(3-amino-3,6-dideoxy-α-L-mannopyranosyl)-oxyj-14,21- -dihydroxy-(3β,5β, 14β,20R)-24-nor-cholanic acid. Operating as in Example 1 but employing 2,4-di-0-acetyl-3,6- dideoxy-3-trifluoroacetamido-α-L-mannopyranosyl bromide, the title compound was obtained in 75% yield. EXAMPLE 22 3- 3-amino-3,6-dideoxy-α-L-mannopyranosyl)oxyj " -14,21- -dihydroxy-(3B,5β,14β,20R)-24-nor-cholanic acid lactone. Operating as in Example 2 but employing 3-£(3-a_nino-3,6- * -dideoxy-α-L-mannopyranosyl)oxy|-14,21-dihydroxy-(38,58, 14β,20R)-24-nor-cholanic acid, the title compound was obtained in 80% yield. EXAMPLE 23 3-C(3-amino-3,6-dideoxy-α-L-mannopyranosyl)oxyj-14,21-dihydroxy- -(38,58,148,20S)-24-nor-cholanic acid. Operating as in Example 3 but employing 2,4-di-0-acetyl-3,6- -dideoxy-3-trifluoroacetamido-α-L-mannopyranosyl bromide, the title compound was obtained in 60% yield. EXAMPLE 24 3- 3-amino-3,6-dideoxy-α-L-mannopyranosyl)oxyj-14,21-dihydroxy- -(38,56,14β,20S)-24-nor-cholanic acid lactone. Operating as in Example 2 but employing 3- (3-amino-3,6-dideoxy- -α-L-mannopyranosyl)oxy]-14,21-dihydroxy-(38,58,146,20S)-24-nor- cholanic acid, the title compound was obtained in 95% yield. EXAMPLE 25 3-[ " (3-amino-3, 6-dideoxy-α-L-mannopyranosyl)oxyJ * -21-hydroxy- 14 (3B,5β,20R)-Δ -24-nor-cholenic acid. Operating as in Example 5 but employing 2,4-di-0-acetyl-3,6- -dideoxy-3-trifluoroacetamido-α-L-mannopyranosyl bromide, the title compound was obtained in 60% yield. EXAMPLE 26 3- r( 3-amino-3 , 6-dideoxy-α-L-mannopyranosyl) oxy] — 21 -hydroxy- 14 (36,55, 20R) -Δ -24-nor-cholenic acid lactone. Operating as in Example 2 but employing 3-{](3-amino-3,6- -dideoxy-α-L-mannopyranosy1)oxy -21-hydroxy-(3B ,5B,20R) - 1 144 „, --ΔΔ --2244--nnoorr--cc]holenic acid, the title compound was obtained in 80% yield. EXAMPLE 27 3- (3-amino-3,6-dideoxy-α-L-mannopyranosyl)oxy3-21-hydroxy- 14 (3B,5β,2QS) -Δ -24-nor-cholenic acid. Operating as in Example 7, but employing 2,4-di-O-acetyl- -3,6-dideoxy-3-trifluoroacetamido-α-L-mannopyranosyl bromide, the title compound was obtained in 66% yield. EXAMPLE 28 3-[7( 3-amino-3 , 6-dideoxy-α-L-mannopyranosyl) -oxy -21 - 14 -hydroxy- ( 35 , 58 , 2QS ) -Δ -24-nor-cholenic acid lactone . Operating as in Example 2 , but employing 3- {_(3-amino- -3 , 6-dideoxy-α-L-mannopyranosyl) oxyj -21 -hydroxy- ( 3 β , 5 β , 1 144 2200SS))--ΔΔ --2244--nnoorr--cchhoolleernic acid, the title compound was obtained in 74% yield. EXAMPLE 29 3- (3-amino-3,6-dideoxy-α-D-altropyranosyl)oxyj-14,21- dihydroxy-(38,58,148,20R)-24-nor-cholanic acid. Operating as in Example 1, but employing 3,6-dideoxy-2,4- -di-O-acetyl-3-trifluoroacetamido-α-D-altropyranosyl bro¬ mide, the title compound was obtained in 70% yield. EXAMPLE 30 3-f(3-aminp-3,6-dideoxy-α-D-altropyranosyl)oxy -14,21- dihydroxy-(3B,5B,14B,20R)-24-nor-cholanic acid lactone. Operating as in Example 2, but employing 3- I (3-amino-3,6- -dideoxy-α-D-altropyranosyl)oxyj-14,21-dihydroxy-(38,58, 14β,20R)-24-nor-cholanic acid, the title compound was obtained in 75% yield. EXAMPLE 31 3~C(3-amino-3, 6-dideoxy-α-D-altropyranosyl)oxy * ]-14,21- -dihydroxy-(3B,5β,14B,20S)-24-nor-cholanic acid. Operating as in Example 3, but employing 3,6-dideoxy-2,4- -di-O-acetyl-3-trifluoroacetamido-α-D-altropyranosyl bro¬ mide, the title compound was obtained in 55% yield. EXAMPLE 32 3-T(3-amino-3, 6-dideoxy-α-D-altropyranosyl)oxy -14,21- -dihydroxy-(3S,58,14B,20S)-24-nor-cholanic acid lactone. Operating as in Example 2, but employing 3- -(3-amino-3,6- -dideoxy-α-D-altropyranosyl)oxyj-14,21-dihydroxy-(38,58, 1 6,20S) -24-nor-cholanic acid, the title compound was obtained in 73% yield. EXAMPLE 33 3~C ( 3-amino-3 , 6-dideoxy-α-D-altropyranosyl) oxyj -21 -hydroxy- 14 (36,56, ,20R)-Δ -24-nor-cholenic acid. Operating as in Example 5, but employing 3,6-dideoxy-2,4-di- -O-acetyl-3-trifluoroacetamido-α-D-altropyranosyl bromide, the title compound was obtaiend in 75% yield. EXAMPLE 34 3-Q(3-amino-3,6-dideoxy-α-D-altropyranosyl)oxy}-21-hydroxy- 14 (38,58, 20R)-Δ -24-nor-cholenic acid lactone. Operating as in Example 2, but employing 3- j " (3-amino-3,6- -dideoxy-α-D-altropyranosyl)oxyj-21-hydroxy-(3β,5β,14β,20R) - 14 -Δ -24-nor-cholenic acid, the title compound was obtained in 77% yield. EXAMPLE 35 3-C(3-amino-3,6-dideoxy-α-D-altropyranosyl)oxyJ-21-hydroxy- 14 -(38,56, 20S)-Δ -24-nor-cholenic acid. Operating as in Example 7, but employing 3,6-dideoxy-2,4-0- -di-acetyl-3-trifluoroacetamido-α-D-altropyranosyl bromide, the title compound was obtained in 80% yield. EXAMPLE 36 3-[_(3-amino-3,6-dideoxy-α-D-altropyranosyl)oxy]-21-hydroxy- 14 -(36,56, 20S)-Δ -24-nor-cholenic acid lactone. Operating as in Example 2, but employing 3-j~(3-amino-3,6-di- -ι 14 deoxy-u-D-altropyranosyl)oxy|-21-hydroxy-(3β,5β, 48,20S) -Δ -24-nor-cholenic acid, the title compound was obtained in 73% yield. EXAMPLE 37 3- [(3, 6-dideoxy-3-dimethylamino-α-D-altropyranosyl)oxy3- -14, 21-dihydroxy-(38,58,148,20R) -24-nor-cholanic acid. Operating as in Example 1, but employing 3,6-dideoxy-2,4- -di-O-acetyl-3-dimethylamino-α-D-altropyranosyl bromide hydrobromide, the title compound was obtaiend in 77% yield. EXAMPLE 38 3-f(3, 6-dideoxy-3-dimethylamino-α-D-altropyranosyl)oxyl-14,21- -dihydroxy- (38,56,14β,20R) -24-nor-cholanic acid lactone. Operating as in Example 2, but employing 3- L(3,6-dideoxy-3-di- methylamino-α-D-altropyranosyl)oxy -14,21-dihydroxy-(38,58,148, 20R) -24-nor-cholanic acid, the ttile compound was obtained in 80% yield. EXAMPLE 39 3- [ ( 3-amino-2 , 3 , 6-trideoxy-α-D-arabino-hexopyranosyl) oxyj-14 , 21 - -dihydroxy- ( 38 , 5 β, 14 β , 20R) -24-nor-cholanic acid. Operating as in Example 1 , but employing 2 , 3 , 6-trideoxy-3-tri- fluoroacetamido-4-O-trifluotoacetyl-α-D-arabino-hexopyranosyl chloride, a mixture of α and β-glycosides was obtained in 63% yield. The title compound was obtained by crystallization in 30% yield. EXAMPLE 40 3- (3-amino-2,3,6-trideoxy-α-D-arabino-hexopyranosyl)oxyj- 14,21-dihydroxy-(3β,5β,14β,20R)-24-nor-cholanic acid lactone. Operating as in Example 2, but employing 3~L(3-amino-2,3,6- -trideoxy-α-D-arabino-hexopyranosyl)oxy ~ j-14,21-dihydroxy- (3B,5β,14β,20R)-24-nor-cholanic acid, the title compound was obtained in 67% yield. EXAMPLE 41 ' 3-C(3-amino-2,3,6-trideoxy-6-D-arabino-hexopyranosyl)oxyl- 14,21-dihydroxy-(38,58,148,20R) -24-nor-cholanic acid. The residue of the mother liquors obtained in Example 39 was crystallized giving the title compound in 28% yield. EXAMPLE 42 3- (3-amino-2,3,6-trideoxy-6-D-arabino-hexopyranosyl)oxyj- 14,21-dihydroxy-(38,58,14B,20R) -24-nor-cholanic acid lactone. Operating as in Example 2, but employing 3-f(3-amino-2,3,6- -trideoxy-β-D-arabino-hexopyranosyl)oxyj-14,21-dihydroxy-(38, 58,14B,20R)-24-nor-cholanic acid, the title compound was obtained in.73% yield. EXAMPLE 43 3-C(3-amino-2,3,6-trideoxy-α-D-arabino-hexopyranosyl)oxy]- -14,21-dihydroxy-(38,58,148,20S)-24-nor-cholanic aci . Operating as in Example 3, but employing 2,3,6-trideoxy-3- -trifluoroacetamido-4-O-trifluoroacetyl-α-D-arabino-hexopy- ranosyl chloride, the title compound was obtained in 55% yield. EXAMPLE 44 3-Q3-amino-2,3,6-trideoxy-α-D-arabino-hexopyranosyl)oxy]- -14,21-dihydroxy-(35,56,146,20S)-24-nor-cholanic acid lactone. Operating as in Example 2, but employing 3- (3-amino-2,3,6- -trideoxy-α-D-arabino-hexopyranosyl)oxyj-14,21-dihydroxy-(38,56, 146,20S)-24-nor-cholanic acid, the title compound was obtained in 78:% * yield. EXAMPLE 45 3- * (3-amino-2,3,6-trideoxy-α-D-arabino-hexopyranosyl)oxyj-21- 14 -hydroxy-(3β,5β,20R)-Δ -24-nor-cholenic acid. Operating as in Example 5, but employing 2,3,6-trideoxy-3- -trifluoroacetamido-4-O-trifluoroacetyl-α-D-arabino-hexopyra- nosyl chloride, the title compound was obtained in 58% yield. EXAMPLE 46 3-f(3-amino-2,3,6-trideoxy-α-D-arabino-hexopyranosy1)oxyj- 14 -21-hydroxy-(38,5B,20R)-Δ -24-nor-cholenic acid lactone. Operating as in Example 2 f but employing 3-[_(3-amino-2,3,6- -trideoxy-α-D-arabino-hexopyranosyl)oxyj-21-hydroxy-(38,58, 1 1 1444 2200RR))--ΔΔ --2244--1nor-cholenic acid, the title compound was obtained in 75% yield. EXAMPLE 47 3-T(3-amino-2,3,6-trideoxy-α-D-arabino-hexopyranosyl)oxyj-21- -i 4 -hydroxy- (36, 56,20S) -Δ -24-nor-cholenic acid. Operating as in Example 7, but employing 2,3,6-trideoxy-3- -trifluoroacetamido-4-O-trifluoroacetyl-α-D-arabino-hexopyra- nosyl chloride, the title compound was obtained in 60% yield. EXAMPLE 48 3-L(3-amino-2,3,6-trideoxy-α-D-arabino-hexopyranosyl)oxyJ-21- 14 -hydroxy-(36,58,20S) -Δ -24-nor-cholenic acid lactone. Operating as in Example 2, but employing 3- (3-amino-2,3,6- -trideoxy-α-D-arabino-hexopyranosyl)oxy -21-hydroxy-(38,56, 20S)-Δ 14-24-nor-cholenic acid, the title compound was obtained in 75% yield. EXAMPLE 49 3-/T2-amino-2-deoxy-A -D-glucopyranosyl)oxy7-21-hydroxy- -θft,5fe,2QS)-Δ -24-nor-cholenic acid Operating as in Example 7, but employing 2-deoxy-2-diphenyl- oxyphosphorylamino-3,4,6-0-acetyl-λ-D-glucopyranosyl bromide, the title compound was obtained in 55% yield. EXAMPLE 50 3-/T2-amino-2-deoxy- ft -D-glucopyranosyl)oxy7-21-hydroxy- -Oft,5ft,20S)-Δ 1 -24-nor-cholenic acid lactone Operating as in Example 2, but employing 3-/(2-amino-2-deoxy- - -D-glucopyranosyl)oxy7-21-hydroxy-( 5/3,20S)-Δ 14 -24-nor- -cholenic acid, the title compound was obtained in 70% yield, m.p. 192-194°C. EXAMPLE 51 3-/T3-amino-3,6-dideoxy-_i-D-mannopyranosyl)oxy/-21-hydroxy- -Qft,5ft,20S)-Δ 14 -24-nor-cholenic acid Operating as in Example 7, but employing 2,4-di-0-acetyl-3,6- dideoxy-3-trifluoroacetamido-*(-D-mannopyranosylbromide, the title compound was obtained in 65% yield. EXAMPLE 52 3-/T3-amino-3,6-dideoxy-όl-D-mannopyranosyl)oxy7-21-hydroxy- -(3/.,5( ,20S)-Δ 14 -24-nor-chofenic acid lactone Operating as in Example 2, but employing 3-/l3-amino-3,6- _ M 1 1 -dideoxy- 0 -D-mannopyranosyl)oxy7-21-hydroxy-(3 ,53, 0S)- Δ - -nor-cholenic acid, the title compound was obtained in 70% yield, m.p. 200-202°C. EXAMPLE 53 3-/T3-amino-3-deoxy-ol-D-mannopyranosyl ) oxy 7-21 -hydroxy- - ( 3( * ., 5^, 20S ) -Δ 14 -24-nor-cholenic acid Operating as in Example 7, but employing 2,4,6-tri-0-acetil- -3-deoxy-3-trifluoroacstamido-°« -D-mannopyranosyl bromide, the title compound was obtained in 75% yield. EXAMPLE 54 3-/T3-amino-3-deoxy-o^-D-mannopyranosyl)oxy/-21-hydroxy- Q- -(3(\5(V20S)-Δ 14 -24-nor-cholenic acid lactone Operating as in Example 2, but employing 3-/T3-amino-3- -deoxy-o(-D-mannopyranosyl)oxy7-21-hydroxy-(3/,5 ,20S)-Δ. - -nor-cholenic acid, the title compound was obtained in 85% yield, m.p. 251-253°C. 5 EXAMPLE 55 3-/T3-amino-3-deoxy-o(-D-mannopyranosyl)oxy7-21-hydroxy- -(3ft, Sh,20R)- Δ 14 -24-nor-cholenic acid Operating as in Example 5, but employing 2,4,6-tri-O-acetyl- -3-deoxy-3-trifluoroacetamido-o^ -D-mannopyranosyl bromide, Q . the title compound was obtained in 50% yield. EXAMPLE 56 3-/T3-amino-3-deoxy-t^-D-mannopyranosyl)oxy7-21-hydroxy- -(3fr,5ft,20R)- 14 -24-nor-cholenic acid lactone Operating as in Example 2, but employing 3-/T3-amino-3- 5 -deoxy-c-D-mannopyranosyl)oxy7-21-hydroxy-(3 ,δA,20R)- - 14 -24-nor-cholenic acid, the title compound was obtained in 70% yield, m.p. 230-232°C. EXAMPLE 57 3-/T3-amino-3,6-dideoxy-<-.-L-altropyranosyl)oxy7-21-hydroxy- -(3/-iι,5^>,20S)-Δ 1 -24-nor-cholenic acid Operating as in Example 7, but employing 3,6-dideoxy-2,4-0- -di-acetyl-3-trifluoro-acetamido-c^-L-altropyranosylbromide, the title compound was obtained in 75% yield. EXAMPLE 58 3-/73-amino- ,6-dideoxy-β*.-L-altropyranosyl)ox3r/-21-hydroxy- -(3( * , 5ft, 20S)-Δ 14 -24-nor-cholenic acid lactone Operating as in Example 2, but employing 3-/( " 3-amino-3,6- -dideoxy- o*! -L-altropyranosyl)oxy7-21-hydroxy-(3^, 5 ,20S)- -Δ1 _24_ nor _ c ] o en i c acid, the title compound was obtained in 72% yield, m.p. 192-194°C. EXAMPLE 59 3-/r3-amino-3,6-dideoxy-o-L-altropyranosyl)oxy7-21-hydroxy- -(3ft,5^ > 20R)-Δ 14 - 24-nor-cholenic acid Operating as in Example 5, but employing 3,6-dideoxy-2,4-0- -di-acetyl-3-trifluoroacetamido-o. -L-altropyranosyl bromide, the title compound was obtained in 65% yield. EXAMPLE 60 _ 3-/T3-amino-3,6-dideoxy-c-L-altropyranosyl)oxy7- 1-hydroxy- -θ ,5ft,20R)- Δ 1 -24-nor-cholenic acid lactone Operating as in Example 2, but employing 3-/(3-amino- -3,6-dideoxy- d-L-altropyranosyl)oxy7-21-hydroxy-(3/.,5S,20R)- - Δ 14-24-nor-cholenic acid, the title compound was obtained in 83% yield, m.p. 152-155°C. EXAMPLE 61 3-/T3-amino-2,3,6-trideoxy- -D-arabino-hexopyranosyl)-oxy7- Z j r _4 — -21-hydroxy-(3ft,5( * !>,20S)-Δ -24-nor-cholenic acid Operating as in Example 7, but employing 2,3,6-trideoxy-3- -trifluoroacetamido-4-O-trifluoroacetyl-^i -D-arabino-hexo- pyranosyl chloride, the title compound was obtained in 62% yield. EXAMPLE 62 3-/T3-amino-2,3,6-trideoxy-o. -D-arabino-hexopyranosyl)oxy7- ■ -≥l-hydroxy-(3ft,5ft,20S)-Δ 14 -24-nor-cholenic acid lactone Operating as in Example 2, but employing 3-/l3s-amino-2,3,6- -trideoxy-o. -D-arabino-hexopyranosyl)oxy7-21-hydroxy-(3 , 5 A,20S)- 14 - I I -A -24-nor-cholenic acid, the title compound was obtained in 72% yield, m.p. 222-226°C. EXAMPLE 63 3-/T3-amino-2,3,6-trideoxy-c -D-arabino-hexopyranosyl)oxy7- -21-hydroxy-(3 ,5 ,20R)- Δ 14 -24-nor-cholenic acid Operating as in Example 5, but employing 2,3,6-trideoxy-3- -trifluoroacetamido-4-O-trifluoroacetyl- d-D-arabino-hexo- pyranosylchloride, the title compound was obtained in 68% yield. EXAMPLE 64 3-/T3-amino-2 , 3 , 6-trideoxy- o^ -D-arabino-hexopyranosyl ) - oxy7-21-hydroxy-(:_Λ, 5/3, 20R)- Δ 1 -nor-cholenic acid lactone Operating as in Example 2, but employing 3-/(3-amino-2, 3 , 6- -trideoxy-ci -D-arabino-hexopyranosyl )-oxy7-21-hydroxy - -(3Λ, 5&, 20R)- Δ -24-nor-cholenic acid, the title comp was obtained in 78% yield, m.p. 192-195°C. The invention is illustrated further in the below formulation examples: Formulation 1 Ingredient Part compound of the formula (I) 45 starch 10 lactose 45 The ingredients are mixed thoroughly, and tablets or capsules are formulated from the mixture. Formulation 2 Ingredient Part compound of the formula (I) 10 lactose 75 magnesium oxide (MgO ^ > 96%) 15 The above ingredients are mixed thoroughly, and powders or fine granules are formed from the mixture. Formulation 3 Ingredient Part compound of the formula (I) 1 surface active agent 1 physiological saline 98 The above ingredients are mixed under warming, and dis¬ pensed under sterile conditions into ampoules for use as injections.

Claims: CLAIMS : A compound having the general formula I wherein either R. represents a hydroxy group or an alkoxy group having from l to 4 carbon atoms and R, represents a hydrogen atom or an alkyl group having from l to 4 carbon atoms, or R-> and R2 taken together represent a chemi¬ cal bond; R, represents an aminodeoxy or aminodideoxy or aminotrideoxy sugar residue of the D or L series; and either R. represents a hydroxy group and R,- represents a hydrogen atom; or R. and - taken together represent a chemical bond; or a pharmaceutically acceptable salt thereof. 2. A compound according to formula I wherein the sugar residue is alkyl substituted. 3. A compound according to claim 1 wherein said sugar residue is a 2-amino or 2-alkylamino-2-deoxyhexopyranosyl, 3-amino or 3-alkylamino-3-deoxy-hexopyranosyl, 3-amino or 3-alkylamino-3,6-dideoxy-hexopyranosyl, 3-amino or 3-alkylamino-2,3,6-trideoxy-hexopyranosyl or 4-amino or 4-alkylamino-2,4,6-trideoxy-hexopyranosyl residue of the D or L series. 4. A compound according to claim 1 wherein R-, repre¬ sents hydroxy, methoxy, ethox , propoxy or butoxy group and - represents methyl, ethyl, propyl or butyl group or. hydrogen atom. 5. A process for the preparation of a compound having the general formula I as defined in claim 1, which process comprises condensing a steroid having the general formula wherein R, and 5 are as defined in claim 1 with a protected 1-halo derivative of an aminodeoxy, aminodideoxy or a inotrideoxy sugar of the D or L series and removing the protecting groups from the resultant compound. 6. A process according to claim 5 wherein the protec¬ ting group is removed with a base. 7. A process according to claim 6 wherein the condensa¬ tion is carried out in an organic solvent in presence of a catalyst and of a drying agent. 8. A process according to claim 7 wherein the condensa¬ tion is carried out in chloroform, methylene dichloride, benzene, toluene, acetonitrile or nitromethane, in the presence of silver oxide or carbonate or trifluormethane- sulphonate, Fetizon's reagent or .mercuric cyanide or bromide, and of drierite or a molecular sieve, or using the azeotropic distillation method, at a temperature of from -5°C to 100°C. 9. A process according to any of claims 5 to 8 wherein the base is a hydroxide or methoxide of potassium or of sodium or of barium or is triethylamine, and the removal of the protecting groups is effected at room temperature. 10. A process according to any of claims 5 to 9 further comprising cyclizing the resultant compound to form the corresponding lactone. 11. A process according to claim 10 wherein the cycliza¬ tion is carried out in hydrochloric acid at room tempera¬ ture and at pH 1-2 for a period of from three to five hours. 12. A pharmaceutical composition comprising a compound having the general formula I as defined in claim 1 or a pharmaceutically acceptable salt of such a compound in admixture with a pharmaceutically acceptable diluent or carrier. 13. A pharmaceutical composition according to claim 12 for use in the treatment of hypertension. 14. The use of compounds having the general formula I or the salts thereof for the making of medicaments against hypertension.

Inventors: CHIODINI LAURA, FERRARI PATRIZIA, GOBBINI MAURO, MANTEGANI SERGIO, RUGGIERI DANIELA, TEMPERILLI ALDEMIO, TRAQUANDI GABRIELLA, CHIODINI, LAURA, FERRARI, PATRIZIA, GOBBINI, MAURO, MANTEGANI, SERGIO, RUGGIERI, DANIELA, TEMPERILLI, ALDEMIO, TRAQUANDI, GABRIELLA
Applicants: ERBA FARMITALIA, FARMITALIA CARLO ERBA S.P.A.
Application year: 1987
Main classification: C07J41
IPC codes: A61K31, C07J1, C07J41